Danaher Corp. has a market cap of $33.01 billion; its shares were traded at around $50.47 with a P/E ratio of 21.8 and P/S ratio of 2.5. The dividend yield of Danaher Corp. stocks is 0.2%. Danaher Corp. had an annual average earning growth of 13.7% over the past 10 years. GuruFocus rated Danaher Corp. the business predictability rank of 3.5-star.Hedge Fund Gurus that owns DHR: Steven Cohen of SAC Capital Advisors, George Soros of Soros Fund Management LLC, Louis Moore Bacon of Moore Capital Management, LP, Paul Tudor Jones of The Tudor Group. Mutual Fund and Other Gurus that owns DHR: Ruane Cunniff of Ruane & Cunniff & Goldfarb Inc, Jeremy Grantham of GMO LLC, RS Investment Management, Mario Gabelli of GAMCO Investors, Pioneer Investments.
Highlight of Business Operations: Sales in 2010 by geographic destination were: North America, 49% (including 45% in the U.S.); Europe, 28%; Asia/Australia, 17%; and other regions, 6%. For additional information regarding our segments and sales by geography, please refer to Note 19 in the Consolidated Financial Statements included in this Annual Report.
Our Test & Measurement segment is a leading global provider of electronic measurement instruments, monitoring, management and optimization tools for communications networks and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment and communications networks and services. Customers for these products and services include manufacturers of electronic products; electrical engineers and technicians; research and development operations; operators of and service providers for local and wide area networks; and communications network equipment manufacturers. Sales for this segment in 2010 by geographic destination were: North America, 54%; Europe, 20%; Asia/Australia, 20%; and other regions, 6%.
Our Environmental segment provides products that help protect our water supply and air quality and serves two primary markets: water quality and retail/commercial petroleum. Sales for this segment in 2010 by geographic destination were: North America, 51%; Europe, 26%; Asia/Australia, 14%; and other regions, 9%. Our Environmental segment consists of the following lines of business.
Our Life Sciences businesses offer a broad range of research and clinical tools that are used by scientists to study cells, and the components of cells, to gain a better understanding of complex biological matters. Pharmaceutical and biotechnology companies, universities, medical schools and research institutions use these tools and this information to study the causes of disease, identify new therapies and test new drugs and vaccines. Our Diagnostics businesses offer a broad range of analytical instruments, reagents, consumables, software and services that are used to diagnose disease, make treatment decisions and monitor patients in hospitals and other critical care settings. Customers of these businesses include hospitals, physicians offices and reference laboratories. Sales for this segment in 2010 by geographic destination were: Europe, 36%; North America, 33%; Asia/Australia, 27%; and other regions, 4%.
Read the The complete Report